Top movers in Thursday's pre-market session Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Why Y-mAbs Therapeutics Stock Got Mashed on Monday The company didn't quite meet expectations for either trailing results or full-year guidance.
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024 YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024 YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
